首页> 外国专利> METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA

METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA

机译:治疗急性髓性白血病的方法和组合物实施方案

摘要

Disclosed herein are embodiments of a method and pharmaceutical composition for treating acute myeloid leukemia (AML). In particular, the method embodiments comprise treating AML with 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, alone or in combination with one or more therapeutic agents that themselves are effective for treating AML. Also disclosed are embodiments of a pharmaceutical composition comprising 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, either as the sole therapeutic agent or in combination with one or more therapeutic agents effective for treating AML.
机译:本文公开了用于治疗急性髓性白血病(AML)的方法和药物组合物的实施方案。 特别地,该方法实施方案包括用6 - ((5-氟-2-((3,4,5-三甲氧基苯基)氨基)嘧啶-4-基)氨基)-2,2-二甲基-2H-吡啶胺治疗AML [3,2-b] [1,4]恶化-3(4h) - 单独或与一种或多种治疗剂组合,本身是有效治疗AML的一种或多种治疗剂。 还公开了包含6 - ((5-氟-2-((3,4,5-三甲氧基苯基)氨基)嘧啶-4-基)氨基)-2,2-二甲基-2H-吡啶的药物组合物的实施方案 3,2-B] [1,4]恶唑汀-3(4h) - 酮作为唯一治疗剂或与一种或多种治疗剂组合用于治疗AML的治疗剂。

著录项

  • 公开/公告号US2022000880A1

    专利类型

  • 公开/公告日2022-01-06

    原文格式PDF

  • 申请/专利权人 RIGEL PHARMACEUTICALS INC.;

    申请/专利号US201917290741

  • 申请日2019-10-31

  • 分类号A61K31/5383;A61K31/675;A61K31/5377;A61K31/7076;A61K31/704;A61K31/7068;A61K31/635;A61K31/4745;A61K31/553;A61K38/20;A61K39/395;A61K31/417;A61K31/53;A61P35;

  • 国家 US

  • 入库时间 2022-08-24 23:15:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号